Malaysia’s Breast Cancer Screening Gap Draws Attention As Minister Cites One-In-23 Risk
Registry figures cover earlier years, while access to mammograms and timely assessment remain central to the current awareness campaign.
Malaysia's breast cancer awareness campaign has brought renewed attention to a large screening gap, after Women, Family and Community Development Minister Nancy Shukri cited a one-in-23 risk and said most women aged 40 and older had never undergone a mammogram.
Speaking in Kuching on Oct. 25, Nancy compared the risk with an earlier one-in-27 estimate, drawing on national cancer registry reports covering 2012-2016 and 2017-2021, Bernama reported. The figures describe findings from those registry periods. They are not a measurement of a sudden increase during October 2026.
Nancy cited the National Health and Morbidity Survey 2023 in saying 71% of women aged 40 and older had never had a mammogram. She also said 46% did not practise breast self-examination. The figures raise questions about access and early detection but do not show why every woman in the survey had not been screened.
She pointed to the National Population and Family Development Board's mammogram subsidy programme, introduced in 2007 and later strengthened through a wider reproductive-cancer awareness initiative. As of Sept. 30, she said 598,919 women nationwide had benefited, including 90,075 in Sarawak. A cumulative programme total is different from the number screened in a single year.
The World Health Organization distinguishes early diagnosis from screening. Early diagnosis concerns awareness of symptoms, timely clinical evaluation and referral for treatment. Screening uses mammography in an apparently healthy population to detect disease before symptoms become recognisable. The two approaches are related but do not replace one another.
WHO says an abnormal breast lump warrants medical attention even when it is painless. Changes in breast size or shape, skin changes, nipple changes or abnormal discharge can also be warning signs. Many lumps are not cancer, which is why assessment matters rather than an assumption based on pain or appearance alone.
Most women diagnosed with breast cancer do not have a known family history, according to WHO. That does not make family history irrelevant; it means its absence cannot provide reassurance on its own. Decisions about screening and diagnostic tests depend on age, symptoms and individual risk assessment.
The current programme information published on Portal Manfaat describes eligibility for Malaysian citizens and permanent residents aged 40-70, with a route for women aged 35-39 who have a family history of breast cancer before age 40 and are referred following medical assessment. The listed criteria do not mean every woman automatically receives the same test at the same interval.
The programme page says eligible women can apply through LPPKN's Nur Sejahtera clinics for an initial clinical assessment and referral to registered mammogram centres. It lists free screening for qualifying high-risk women with household income of RM10,000 or less and a RM50 subsidy for eligible women above that income level. Applicants need the programme's actual eligibility assessment rather than relying only on the income figure.
Consultant general surgeon Dr. Ong Kheng Wah offered a related warning in an Oct. 6 Malay Mail report: the way a lump feels is not a reliable diagnosis. He described clinical examination, breast imaging and tissue sampling when indicated as components of assessment. Some benign lumps can feel firm, while some cancers can remain mobile.
That report put the registry's one-in-23 figure in a more precise frame: lifetime risk before age 75. It also reported that 50.5% of staged cases in the 2017-2021 registry were diagnosed at stage III or IV. That percentage concerns cases with staging information, not half of all Malaysian women or all possible breast lumps.
Support after diagnosis is another part of the pathway. The American Cancer Society's 2026 fact sheet for health professionals identifies concerns that can include treatment side effects, fatigue, changes in appearance, fertility, fear of recurrence and the financial burden on patients and families. Screening participation alone cannot measure whether those needs are met.
That broader perspective is relevant when interpreting awareness campaigns: finding a possible cancer is the beginning of further assessment, and a diagnosis may involve decisions over a sustained course of care. A programme's screening total does not by itself describe treatment completion, a patient's quality of life or the time between an abnormal result and specialist care.
Comparisons of survival figures also need matching definitions and periods. A statement about early-stage survival is different from a national five-year relative-survival measure, and neither can predict an individual's outcome without the clinical details. The appropriate use of such statistics is to explain why prompt assessment matters while preserving the uncertainty attached to a particular diagnosis.
The immediate public-health issue is connecting awareness with an accessible route to clinical evaluation. The new ministerial remarks draw attention to a continuing gap, while the underlying registry and survey dates show the evidence's limits. For an individual with a new or unusual change, waiting for an awareness event or assuming a painless lump is harmless would miss the purpose of early diagnosis.